Matrix left with half a loaf

With a second non-approvable letter for AccuSite Injectable Gel from the FDA in hand, Matrix Pharmaceutical Inc. now is stuck with a product that is on the market in Europe and apparently nowhere to go in the U.S.

The company last week said it has halted development of the compound for genital warts in the U.S. indefinitely. While revenue projections will be hit, the real complication is that AccuSite is already on the market in the U.K., and has been approved for marketing

Read the full 820 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE